sovateltide   Click here for help

GtoPdb Ligand ID: 3886

Synonyms: IRL 1620 | IRL-1620 | IRL2620 | PMZ-1620 | SPI-1620 | Suc[Glu9,Ala11,15]ET-110-21 | Tycamzzi®
Approved drug
sovateltide is an approved drug (India CDSCO (2023))
Compound class: Peptide
Comment: Sovateltide (previously IRL-1620 and PMZ-1620) is a selective endothelin-B receptor (ETB) agonist. It is proposed as a mechanism to improve formation of new mature neurons and blood vessels in acute cerebral ischemia [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

sovateltide is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCC(C(C(=O)NC(C(=O)NC(C(=O)O)Cc1c[nH]c2c1cccc2)C(CC)C)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CCC(=O)O)CC(=O)O)CCC(=O)O)CCC(=O)O)C)Cc1ccc(cc1)O)Cc1ccccc1)C)Cc1nc[nH]c1)CC(C)C)CC(=O)O)C
Isomeric SMILES CC[C@@H]([C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)Cc1c[nH]c2c1cccc2)[C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCC(=O)O)CC(=O)O)CCC(=O)O)CCC(=O)O)C)Cc1ccc(cc1)O)Cc1ccccc1)C)Cc1nc[nH]c1)CC(C)C)CC(=O)O)C
InChI InChI=1S/C86H117N17O27/c1-11-44(7)71(84(127)100-63(86(129)130)35-50-39-88-54-21-17-16-20-53(50)54)103-85(128)72(45(8)12-2)102-82(125)62(38-69(114)115)98-78(121)57(32-42(3)4)96-80(123)60(36-51-40-87-41-89-51)95-73(116)46(9)91-77(120)58(33-48-18-14-13-15-19-48)97-79(122)59(34-49-22-24-52(104)25-23-49)99-83(126)70(43(5)6)101-74(117)47(10)90-75(118)55(26-29-65(106)107)93-76(119)56(27-30-66(108)109)94-81(124)61(37-68(112)113)92-64(105)28-31-67(110)111/h13-25,39-47,55-63,70-72,88,104H,11-12,26-38H2,1-10H3,(H,87,89)(H,90,118)(H,91,120)(H,92,105)(H,93,119)(H,94,124)(H,95,116)(H,96,123)(H,97,122)(H,98,121)(H,99,126)(H,100,127)(H,101,117)(H,102,125)(H,103,128)(H,106,107)(H,108,109)(H,110,111)(H,112,113)(H,114,115)(H,129,130)/t44-,45-,46-,47-,55-,56-,57-,58-,59-,60-,61-,62-,63-,70-,71-,72-/m0/s1
InChI Key DXPHNGAMYPPTBJ-TZMIJSMNSA-N
No information available.
Summary of Clinical Use Click here for help
PMZ-1620 was advanced to clinical evaluation. It was first approved by the India Central Drugs Standard Control Organization (CDSCO) in May 2023 [2]. It is indicated as a treatment for acute cerebral ischemic stroke (ACIS) that is to be administered within 24h of stroke onset.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04046484 PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients Phase 2 Interventional Pharmazz, Inc.
NCT04054414 PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury Phase 2 Interventional Pharmazz, Inc.
NCT04047563 Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke Phase 3 Interventional Pharmazz, Inc.